All Stories

  1. Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up
  2. Trends in publication and collaboration of health-themed systematic reviews before and during the COVID-19 pandemic: A bibliometric study
  3. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
  4. Overt and occult hepatitis B virus infection detected among chronic kidney disease patients on haemodialysis at a Tertiary Hospital in Ghana
  5. Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV
  6. Acute liver failure in low-income and middle-income countries
  7. HIV-1 RNA levels in semen of people on ‘short-cycle’ antiretroviral therapy
  8. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients
  9. Serum 25‐hydroxyvitamin D and hyaluronic acid levels as markers of fibrosis in patients with chronic liver disease at the main tertiary referral hospital in Ghana: A case‐control study design
  10. Medicine should be learned in a conducive environment
  11. Global research profile on monkeypox-related literature (1962–2022): A bibliometric analysis
  12. Monkeypox: Immune response, vaccination and preventive efforts
  13. Letter to the Editor: Dolutegravir Monotherapy and Body Weight Gain in Antiretroviral Naïve Patients
  14. Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia
  15. Acute severe hepatitis of unknown etiology in children: A mini-review
  16. Global multi-stakeholder endorsement of the MAFLD definition
  17. Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID‐19 infections?
  18. Research priorities to reduce the impact of COVID-19 in low- and middle-income countries
  19. Chronic liver diseases must be reduced worldwide: it is time to act
  20. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan
  21. Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy
  22. Prevalence of liver fibrosis using transient elastography in the general population in Cambodia: a pilot study
  23. Mini-review: Silico-tuberculosis
  24. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection
  25. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor
  26. Violence Against Healthcare Workers: A Worldwide Phenomenon With Serious Consequences
  27. Acute liver failure
  28. Commentary: Systemic Lupus Erythematosus in Native sub-Saharan Africans: A Systematic Review and Meta-Analysis
  29. HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa
  30. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana’s healthy population
  31. Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
  32. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients
  33. DRIVE-AHEAD Trial’s Results and the Need for a More Appropriate Comparator Drug
  34. Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients
  35. Orphan drugs
  36. Khat-related liver disease in sub-Saharan Africa: neglected, yet important – Authors' reply
  37. Patient-centered Care and Treatment in HIV Infection
  38. Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?
  39. Defensive medicine: It is time to finally slow down an epidemic
  40. Liver cirrhosis in sub-Saharan Africa: neglected, yet important
  41. “High” antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART
  42. Detection of Hepatitis E Antibodies in Kazakhstan: A Pilot Study
  43. The Expanding Therapeutic Perspective of CCR5 Blockade
  44. Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life
  45. Febrile rhabdomyolysis of unknown origin in refugees coming from West Africa through the Mediterranean to Calabria, Italy
  46. Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV ‐1‐infected patients
  47. Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up
  48. Cerebral palsy: a multidisciplinary, integrated approach is essential
  49. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient
  50. End-stage liver disease in eastern Europe and central Asia: action is needed
  51. Treatment of Acute Liver Failure in Resource-Constrained Settings without Transplantation Facilities Can Be Improved
  52. Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load
  53. Tuberculosis-immune reconstitution inflammatory syndrome
  54. Liver diseases in sub-Saharan Africa: the importance of dedicated public clinics
  55. Understanding the HIV/AIDS Atripla drug components interaction with human plasma.
  56. Liver disease in patients with HIV in sub-Saharan Africa
  57. Raltegravir/nevirapine dual therapy at reduced doses as ‘maintenance’ treatment in virally suppressed HIV-infected patients
  58. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act
  59. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study
  60. Virological Efficacy of a Reduced Dose of Nevirapine in a Small Cohort of Suppressed HIV-1–Infected Patients
  61. Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
  62. Efavirenz dose reduction in HIV-infected patients
  63. Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up
  64. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
  65. Management of chronic hepatitis B in children: An unresolved issue
  66. Comparative chromatography–mass spectrometry studies on the antiretroviral drug nevirapine—Analytical performance characteristics in human plasma determination
  67. Thrombotic Thrombocytopenic Purpura-Haemolytic Uremic Syndrome and pregnancy
  68. A Maintenance Dose of Atazanavir/Ritonavir 200/100 mg Once Daily Is Effective in Virologically Suppressed HIV-1–Infected Patients
  69. Efficacy of a Reduced Dose of Darunavir/Ritonavir in a Small Cohort of Antiretroviral-Naïve HIV-Infected Patients
  70. Cancer control in Africa: which priorities?
  71. Limited Adherence to Antiretroviral Regimens in an Italian Cohort
  72. Can HIV-1 viral interference be used therapeutically?
  73. Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries
  74. Isoniazid preventive therapy in human immunodeficiency virus infection [Correspondence]
  75. Efavirenz dose reduction in HIV-infected patients
  76. Antiretroviral Therapy-Associated Diseases Are Common in the Long-Term
  77. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
  78. Efficacy of Lopinavir-Ritonavir Reduced Dose in HIV-Infected Patients
  79. Tuberculosis and cancer: a complex and dangerous liaison
  80. Stroke: a realistic approach to a growing problem in sub-Saharan Africa is urgently needed
  81. Can antiretroviral therapy be safely interrupted and, if so, when?
  82. Silica Exposure and Silicosis: Action is Needed Now
  83. Antiretroviral therapy in low-resource settings
  84. Time for universal HIV and HBV screening for patients with cancer
  85. Editorial: [Challenges in Infectious Diseases in Low and Middle-Income Countries]
  86. The challenge of lymphomas in sub-Saharan Africa
  87. PriorMycobacterium aviumcomplex infection is linked to immunological nonresponsiveness in HIV-infected patients on highly active antiretroviral therapy
  88. Lymph nodes and pathogenesis of infection with HIV-1
  89. The need for new antibiotics
  90. No Influence of Nevirapine on Vitamin D Deficiency in HIV-Infected Patients
  91. The bacterium that could cause cancer
  92. Diagnosis, management and outcome of clinically- suspected spinal infection
  93. Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response
  94. Human herpesvirus type 6 hepatitis or familiar intrahepatic cholestasis: the importance of follow-up
  95. Viral Encephalitis: Etiology, Clinical Features, Diagnosis and Management
  96. Micafungin - The newest echinocandin
  97. Letter to the Editor: Darunavir-Etravirine-Raltegravir as Salvage Combination Therapy in a Heavily Pretreated HIV-Infected Patient
  98. Perspectives in therapy for hepatitis C
  99. Lung infections after cancer chemotherapy
  100. Aminotransferases as predictors of mortality
  101. Does tenofovir increase efavirenz hepatotoxicity?
  102. Initial Hospitalization and Adherence to Highly Active Antiretroviral Therapy
  103. Voluntary or Universal HIV Testing in Italy?
  104. Etravirine
  105. Life-threatening, Multiple Hypersensitivity Reactions Induced by Rifampicin in One Patient with Pulmonary Tuberculosis
  106. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption
  107. Selective Drug Taking During Combination Antiretroviral Therapy
  108. Intracranial mass lesions in HIV/AIDS patients from developing countries endemic for neurocysticercosis
  109. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults
  110. Co-occurrence of chronic hepatitis B virus infection and autoimmune hepatitis in a young Senegalese girl
  111. Tenofovir-Associated Kidney Diseases and Interactions between Tenofovir and Other Antiretrovirals
  112. Infections and thalassaemia
  113. Hyperacute Unilateral Gonococcal Endophthalmitis in an HIV-Infected Man without Genital Infection
  114. Clinical course of infection with hepatitis C
  115. Human Immunodeficiency Virus-Associated Peripheral Neuropathies
  116. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
  117. Acute liver failure as presenting feature of tyrosinemia type 1 in a child with primary HHV-6 infection
  118. CHILDHOOD HEPATITIS C VIRUS INFECTION.
  119. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients
  120. Cutaneous abscess due to in injection drug user: a case report and review of the literature
  121. Strongyloidiasis in an HIV‐1–Infected Patient after Highly Active Antiretroviral Therapy–Induced Immune Restoration
  122. Tipranavir
  123. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus
  124. Can We Really Identify HIV-1 Long-Term Nonprogressors?
  125. Painful Neuropathy Vasculitis in 2 Patients with Long-Standing Human Immunodeficiency Virus-1 Infection
  126. Early detection of lung cancer in high-risk patients with HIV-1 infection
  127. Autoimmune hemolytic anemia and autoimmune hepatitis associated with parvovirus B19 infection
  128. Is there a role for viruses in triggering autoimmune hepatitis?
  129. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment
  130. Is there a role for TNF-alpha in HIV1-associated lipodystrophy?
  131. Unusual, rapidly growing ulcerative genital mass due to herpes simplex virus in a human immunodeficiency virus-infected woman
  132. Management of Health Care Workers With Blood-Borne Infections
  133. Hepatitis C virus in people with HIV infection
  134. Blood-Borne Viruses and Health Care Workers
  135. Sequelae and Serologic Outcome in Persons with Hepatitis B Virus Infection
  136. Erratum
  137. Infections and solid organ transplant rejection: a cause-and-effect relationship?
  138. Hepatitis C is not a sexually transmissible disease
  139. Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection
  140. Treatment of autoantibody-associated chronic hepatitis C
  141. Hepatitis C is not a sexually transmissible disease
  142. Treatment of autoantibody-associated chronic hepatitis C
  143. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue
  144. Childhood Infections and Autoimmune Diseases
  145. Does hepatitis C virus cause severe liver disease only in people who drink alcohol?
  146. How tainted is medicine?
  147. Full Adherence to HAART: Is It Really Necessary?
  148. BCG efficacy and tuberculin skin testing
  149. A Case of Visceral Leishmaniasis with Protracted Incubation in a Nonendemic Area
  150. Mortality Due to Hepatitis C Virus–Related Cirrhosis in Patients Infected with HIV Type 1: A Role for Alcohol
  151. MHC Class I Molecules and Progression to AIDS
  152. Hepatitis A Virus Infection and Atherosclerosis
  153. Isolated Presence of Antibody to Hepatitis B Core Antigen in Injection Drug Users: Do They Need to Be Vaccinated?
  154. Tuberculous chorioretinitis
  155. Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B
  156. No Increase in Liver Decompensation Risk with Atypical Hepatitis C Virus Antibody Pattern
  157. Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B
  158. HIV-1 progression in hepatitis-C-infected drug users
  159. Effect of pregnancy on chronic hepatitis C
  160. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis
  161. Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital
  162. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes
  163. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
  164. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy
  165. Mediastinal Lymphadenitis due To Cryptococcal Infection In HIV-Positive Patients On Highly Active Antiretroviral Therapy
  166. Correspondence
  167. Adherence to HAART in HIV
  168. Failure of Prophylaxis against PCP in Patients with HIV Infection
  169. Hepatitis Associated with Hepatitis A Superinfection in Patients with Chronic Hepatitis C
  170. Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands
  171. Highly active antiretroviral therapy
  172. Fluconazole penetration into the prostatic fluid of patients with AIDS- associated cryptococcal meningitis
  173. Syphilis in prostitutes from Eastern Europe
  174. Tuberculosis Among Refugees and Displaced People at the Burundi‐Rwanda Border
  175. Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C
  176. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance
  177. Microsporidium Species in Pulmonary Cavity Lesions of AIDS Patient Infected withRhodococcus equi
  178. Comparative evaluation of naturally occurring Pneumocystis carinii pneumonia (PCP) and PCP despite primary chemoprophylaxis in patients with AIDS
  179. The ParaSight™-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria
  180. Aetiology of pneumonia following isolated closed head injury
  181. Steroid and interferon therapy in liver/kidney microsomal antibody-positive patients with chronic hepatitis C
  182. Infection with hepatitis G virus in immunoglobulin recipients
  183. M tuberculosis drug resistance in AIDS
  184. Resolution of autoimmune hepatitis after bone-marrow transplantation
  185. Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data
  186. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients
  187. Lack of Sustained Efficacy of Interferon in Patients with Chronic Hepatitis C
  188. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
  189. Discordant Manifestations of Hepatitis C in Monozygotic Twins
  190. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals
  191. Naturally acquired immunity to Plasmodium falciparum
  192. Multidrug-Resistant Tuberculosis in Patients With AIDS
  193. Multidrug-resistant tuberculosis in patients with AIDS
  194. Pentoxifylline as a Supportive Agent in the Treatment of Cerebral Malaria in Children
  195. West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy
  196. Manifestations of TB to CD4 cell counts.
  197. Prognosis of vertically transmitted pre-core mutant HBV infection
  198. Pneumocystis carinii pneumonia during primary HIV-1 infection
  199. Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection
  200. Transmission of HIV-Associated Tuberculosis to Healthcare Workers
  201. Hepatitis C viraemia with normal liver histology in symptomless HIV-1 infection
  202. Use of fluconazole in the treatment ofCandida albicans hydrocephalus shunt infection
  203. Failure of the 12 months course of antituberculous chemoprophylaxis in HIV infection
  204. Tuberculosis and HIV Infection
  205. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals
  206. Survival after Active Tuberculosis in Patients with HIV Infection
  207. Cellular mechanisms of hepatocyte damage and regulatory mechanisms in autoimmune chronic active hepatitis
  208. Type 2 autoimmune hepatitis and hepatitis C virus infection
  209. HAZARDS OF INTERFERON THERAPY FOR HBV-SERONEGATIVE CHRONIC HEPATITIS
  210. REACTIVATION OF HEPATITIS B IN AIDS
  211. CLINICAL REACTIVATION OF HEPATITIS B IN ANTI-HBs-POSITIVE PATIENTS WITH AIDS
  212. PATHOGENESIS OF TYPE I DIABETES
  213. Serial study of liver-directed autoantibodies and autoreactive T-lymphocytes in acute viral hepatitis B
  214. Sequential studies of pre-S2 antigenemia and anti-pre-S2 antibodies in relation to viral replication in acute hepatitis B followed from the early incubation phase
  215. In vitro effect of TP-1 (a calf thymic extract) on suppressor T-cell function of patients with autoimmune chronic active hepatitis
  216. Relevance of immune mediated mechanisms in progressive alcoholic liver injury
  217. PROSPECTIVE STUDY OF CELLULAR IMMUNITY TO HEPATITIS-B-VIRUS ANTIGENS FROM THE EARLY INCUBATION PHASE OF ACUTE HEPATITIS B
  218. T-CELL INDUCERS OF SUPPRESSOR LYMPHOCYTES CONTROL LIVER-DIRECTED AUTOREACTIVITY
  219. CELL-MEDIATED IMMUNITY AND SUPPRESSOR-T-CELL DEFECTS TO LIVER-DERIVED ANTIGENS IN FAMILIES OF PATIENTS WITH AUTOIMMUNE CHRONIC ACTIVE HEPATITIS
  220. T lymphocyte sensitization to hbcag and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease
  221. ANTIGEN SPECIFIC SUPPRESSOR CELL FUNCTION IN AUTOIMMUNE CHRONIC ACTIVE HEPATITIS